Kornimate/medical-research-clean huggingface dataset:
use of analgesics and pain scores after pediatric adenotonsillectomy

Conditions: Pain, Postoperative; Obstructive Sleep Apnea of Child

Summary: the purpose of the study is to quantify the use of pain medications given to children aged 3 - 12 years as well as their pain level through pain scores after they have undergone a tonsillectomy or adenotonsillectomy surgery at doernbecher children's hospital (dch). we would like to learn more about the pain medications given and the pain scores of children post-surgery for the first 5 days following discharge from the hospital.

you and your child will be enrolled into the study during your child's scheduled surgery at dch. your child's surgery, anesthesia plan, and recovery will not change because of your participation in this study. following discharge from the hospital, the study team will give you two follow-up phone calls that will take approximately 15 minutes. during these phone calls, we will ask you about your child's pain, any nausea or vomiting that has occurred, your child's intake of liquid and food, your child's activity level, and the medications they have been given over the course of the 5 days post-operation. along with talking over the phone, we will ask you to document this information. after the post-operation day 6 phone call, you and your child will not be asked any additional questions for research purposes and we will ask you to return any documents you were given by the study team. within 30 days of your and your child's participation in the study, the research team will pull medical information from your child's electronic medical record. your child's electronic medical record will be reviewed to obtain demographic information such as date of birth, age, weight, ethnicity, medical history, and status information will also be collected such as allergies, potential complications, any pain scores collected during your child's post-anesthesia care unit (pacu) stay, and medical visits. 30 days after your child's surgery, you and your child will no longer be enrolled in this research study.

Eligibility criteria:
inclusion criteria: * child aged 3-12 that is scheduled to undergo tonsillectomy or adenotonsillectomy, with or without ear tubes or parent or guardian of a child aged 3-12 years old that is scheduled to undergo tonsillectomy or adenotonsillectomy, with or without ear tubes exclusion criteria: -

Keywords: tonsillectomy adenotonsillectomy
acute bronchiolitis in infants and allergic asthma

Conditions: Acute Bronchiolitis; Asthma; Allergy

Summary: predicting the risk of allergenic sensitizations and asthma development in the first year of life is difficult. investigator decided to follow prospectively two cohorts of infants with acute bronchiolitis, hospitalized or treated at home, from the epidemic seasons of 2011-2012 and 2015-2017 to know their respiratory evolution, especially if they developed allergen sensitization and / or asthma.

follow-up consultation 6 years after an episode of acute bronchiolitis at clermont-ferrand hospital with: * consultation with a pneumopediatrician: collection of respiratory symptoms, respiratory treatments, evaluation of the atopic site and environmental risk factors for bronchial aggression, especially passive smoking; * physical examination ; * evaluation of precariousness during the same interview with the epices questionnaire; * prick tests with positive control (histamine) and negative (physiological saline) and prick for the main pneumallergens (mites, alternaria, grasses, cat and dog) and trophallergens (egg, milk, fish, soy, wheat, peanut); * blood test with blood count, determination of specific ige (5 pneumallergens and 5 trophallergens), dosage of srage; * fonctionnal respiratory test with reversibility test

Eligibility criteria:
inclusion criteria: - acute bronchiolitis in an infant less than one year old, included in studies kl6 (winter period 2011-2012) or cc16 (winter period 2015-2016) at clermont-ferrand hospital. exclusion criteria: * bronchopulmonary dysplasia; * history of prematurity \<34 as; * mucoviscidosis; * known immune deficiencies; * primary ciliary dyskinesia suspected; * congenital heart disease; * acute renal failure. * refusal of parents to participate

Keywords: allergic asthma acute bronchiolitis allergic sensitization -risk factor
french language validation of the 5-minutes montreal cognitive assessment (moca)

Conditions: Cognitive Symptom; Evaluations, Diagnostic Self

Summary: the aim of the study is to validate a french version of the 5 minutes version of the montreal cognitive assessment as compared to the french full version of this test.

the montreal cognitive assessment (moca) is a test used to detect cognitive impairments. this test is available in different languages including french. a short version (the 5 minutes moca) has also been validated through a phone call use that allows to develop some epidemiological approaches. nevertheless, this short version has not been validated in french. the main aim of the study is to validate the french translation of the short version of the moca as compared the the full french version of the test. to validate the short version, several groups of subjects will be included : healthy subjects, alzheimer disease patients, parkinson or huntington diseases patients as well as diabetic patients. the inclusion of both healthy subjects and patients with different types of cognitive impairments will allow to validate the short version of the test. all subjects and patients will first be submitted to the full version of the moca during a face to face procedure. thirty to forty days later, they will be submitted to the short version of the test through a phone call performed by an independent rater. subgroups of healthy subjects and patients will also be used to determine the test-retest and inter-rater reliability of the short version of the moca.

Eligibility criteria:
inclusion criteria: healthy volunteers * volunteers, bmi \<26 * free from neurological, psychiatric, metabolic or cardiac pathologies; * absence of active metabolic or cardiac diseases, unstabilized under treatment * pregnant test negative patients * patients suffering from pathologies that may be accompanied by cognitive decline or dementia (alzheimer's disease, parkinson's and huntington's disease, diabetes) that meet the usual diagnostic criteria for these diseases; * patients should not start treatment of a new therapeutic class under test exclusion criteria: * pregnant or nursing women. * illiterate subjects * presence of uncorrected visual or auditory disturbances * "alcohol use disorder" observed at the mini international neuropsychiatric inventory (mini); * "substance use disorder" observed at the mini; * participation in a therapeutic trial or in an exclusion period from a previous clinical trial; * patient whose physical or mental condition does not allow them to pass the study tests; * persons under guardianship or under trusteeship; * recent cognitive assessment (less than 6 months) by the classic moca
percutaneous coronary intervention (pci) with drug-eluting stents (des) versus coronary artery bypass graft (cabg) for patients with significant left main stenosis

Conditions: Coronary Stenosis; Coronary Artery Disease

Summary: recent technical advances in percutaneous coronary interventions have made it possible to approach patients with coronary lesions formerly considered to be classical candidates for bypass surgery, e.g. patients with left main coronary stenosis. however, it is still unclear whether the good long-term results achieved with the surgical therapy can be reproduced by an interventional strategy using drug-eluting stents (des). the aim of the current trial is, therefore, to compare the clinical and angiographic results of pci and cabg in patients with left main coronary stenosis.

recent technical advances in percutaneous coronary interventions have made it possible to approach patients with coronary lesions formerly considered to be classical candidates for bypass surgery, e.g. patients with left main coronary stenosis. however, it is still unclear whether the good long-term results achieved with the surgical therapy can be reproduced by an interventional strategy using drug-eluting stents (des). the aim of the current trial is, therefore, to compare the clinical and angiographic results of pci and cabg in patients with left main coronary stenosis. the study was planned as a "non-inferiority" trial based on the hypothesis that pci may be able to reach similar long-term results as compared to cabg.

Eligibility criteria:
inclusion criteria: * significant left main coronary stenosis \>= 50% exclusion criteria: * acute myocardial infarction (stemi \< 48h)

Keywords: left main coronary artery coronary artery disease
treatment of severe secondary tricuspid regurgitation in patients with advance heart failure with caval vein implantation of the edwards sapien xt valve (tricaval)

Conditions: Severe Tricuspid Regurgitation

Summary: the purpose of this study is to assess the efficacy and safety of implanting an edwards sapien xt valve into the vena cava inferior (vci; between right atrium and the hepatic vein) on clinical variables, exercise tolerance and well being in patients with severe tricuspid regurgitation and signs of right heart failure.


Eligibility criteria:
inclusion criteria: * severe symptomatic tricuspid regurgitation with a significant regurgitation jet into the caval and hepatic veins * optimal medical treatment * high surgical risk with sts score ≥ 10 or logistic euroscore i ≥ 15 or any contraindication for conventional valve replacement/repair * nyha class of at least ii * written informed consent exclusion criteria: * vci diameter \> 32 mm * severe left ventricular dysfunction with lvef \< 30% * severe mitral insufficiency * estimated life expectancy \< 12months (360 days) due to carcinoma, chronic liver disease, chronic renal disease or chronic end stage pulmonary disease * evidence of an acute myocardial infarction ≤ 1 month before the intended treatment * evidence of stroke / tia during the last 180 days * leukopenia (wbc \< 3000 cell/ml), anemia (hgb \< 9 g/dl), thrombocytopenia (plt \< 50,000 cells/ml), or any known blood clotting disorder * evidence of an intracardiac mass, thrombus or vegetation * active upper gi bleeding within 1 month (30 days) prior to procedure * patients with an acute emergency * contraindication or hypersensitivity to all anticoagulation regimens, or inability to be anticoagulated for the study procedure * allergy against the use of implanted stent / prosthesis * patient undergoing regular dialysis or a serum creatinine above 3.0 mg/dl * patients unsuitable for implantation because of thrombosis of the lower venous system or vena cava filter * active bacterial endocarditis within 6 months (180 days) of procedure. * women of childbearing potential without highly effective contraception (pearl-index \< 1%) * inability to comply with all of the study procedures and follow-up visits * subjects who are legally detained in an official institute (according to § 20 mpg)
a phase 2 safety and efficacy study of tulisokibart (mk-7240/pra023) in subjects with moderately to severely active ulcerative colitis (mk-7240-005)

Conditions: Ulcerative Colitis

Summary: the purpose of this study is to assess the safety and efficacy of tulisokibart in participants with moderately to severely active ulcerative colitis (uc). after the completion of the 12-week induction, all participants have the option to continue in the open-label extension for up to 170 weeks.


Eligibility criteria:
inclusion criteria: the main inclusion criteria include but are not limited to the following: * confirmed diagnosis of ulcerative colitis (uc) * has moderately to severely active uc as defined by 3-component modified mayo score * must have corticosteroid dependence or have had no response, insufficient response, loss of response, and/or intolerance to at least one of the following therapies: corticosteroid, immunosuppressants, or an approved anti-tumor necrosis factor (anti-tnf), anti-integrin, anti-interleukin 12/23 (anti-il12/23), janus kinase (jak) inhibitor, sphingosine 1-phosphate receptor (s1pr) modulator. exclusion criteria: the main exclusion criteria include but are not limited to the following: * has diagnosis of crohn's disease or indeterminate colitis * has current evidence of fulminant colitis, toxic megacolon, bowel perforation, total proctocoloectomy or partial colectomy * has current or impending need for colostomy or ileostomy * has had surgical bowel resection within 3 months before screening * has past or current evidence of definite low-grade or high-grade colonic dysplasia not completely removed

Keywords: artemis-uc artemis ulcerative colitis
taste acuity and caloric intake after acute morphine administration

Conditions: Taste Sweet; Taste Salty; Feeding Behavior

Summary: this study will investigate the effects of acute morphine administration on taste acuity and how much a person eats. it is hypothesized that there will be a dose dependent decrease in taste acuity and dose dependent increase in food intake associated with acute morphine administration. knowledge from this study will impact the future of feeding behavior and obesity research in the general population. results will also promote exploration of the long-term effect of opioid abuse on taste acuity and feeding behavior in substance abusing populations.


Eligibility criteria:
inclusion criteria: * healthy adult male and female volunteers * ages of 18 to 65 exclusion criteria: * history of drug dependence (including opioid use disorders) * history of taste dysfunction * significant medical or axis i psychiatric disorder * any trauma or surgical procedures to the head or neck region * medication or illicit drug more than 4 out of the last 30 days. * pregnancy * abnormal electrocardiogram findings * negative rating of greater than 40% of the foods available for consumption

Keywords: taste acuity feeding behavior opioid quantitative assessment
post-marketing surveillance study with gsk biologicals' pneumococcal vaccine in healthy infants in philippines

Conditions: Infections, Streptococcal

Summary: the purpose of this post-marketing surveillance study is to evaluate the safety of synflorix™ when administered according to the local prescribing information to healthy filipino infants.


Eligibility criteria:
inclusion criteria: * subjects who the investigator believes that their parents/legally acceptable representative(s) (lar(s)) can and will comply with the requirements of the protocol. * filipino male or female subjects whose age at the first vaccination with synflorix™ in this pms should not be less than 6 weeks of age. * filipino male or female subjects who enter the pms at the second dose should not be less than 10 weeks of age. * filipino male or female subjects who enter the pms at the third dose should not be less than 14 weeks of age. * filipino male or female subjects who enter the pms at the booster dose (i.e. if they have received synflorix™ in the previous dose/s outside the pms) should not be less than 10 months of age. the time interval between the primary vaccination and booster dose should be at least 6 months. for the booster dose, subjects who received pcv-7/-13 or synflorix™ in their primary vaccination series will be allowed to take part in the pms. * written and signed informed consent obtained from the parents/lar(s) of the child. where parents/lar(s) are illiterate, the consent form will be countersigned by a witness. * free of obvious health problems as established by medical history and clinical examination before entering into the study. exclusion criteria: * acute disease and/or fever at the time of vaccine administration. * fever is defined as temperature ≥ 37.5°c (99.5°f) on axillary, infrared or tympanic setting. * subjects with a minor illness (such as mild diarrhoea, mild upper respiratory infection) without fever may, be enrolled at the discretion of the investigator. * history of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine. * history of chronic condition(s) requiring treatment such as cancer or autoimmune diseases. * hypersensitivity to latex (found in syringe-tip cap and plunger). * any contraindications as stated in the prescribing information.

Keywords: pneumococcal vaccine
phenylephrine or norepinephrine for a better hemodynamic stability

Conditions: Hypotension; Fluid Therapy

Summary: a prospective, double-blinded study. the present study consisted in applying stroke volume variation fluid guided therapy to old patients (65 years old) undergoing radical resection of colon surgery. the aim of this study is to compare the effects of norepinephrine and phenylephrine in treating perioperative hypotension, and to find the safest and most effective vasopressor for elderly.

fluid management has a great influence on patient's morbidity, mortality and on the overall outcome.goal directed therapy was proved by multiple studies to be a goal therapy in maintaining a stable hemodynamic state. nevertheless, as the population worldwide is aging, elderly presenting for surgery are also increasing. this population is known for the multiple comorbidities and physiological changes which makes them prone to dehydration and hypotension. that's when we are going to use either norepinephrine in one group or phenylephrine in the other and compare the effects of both vasopressors. parameters we are going to use are: hemodynamic (hr, map, co, ci, svv, sv); tissue oxygenation and perfusion (do2, vo2, ero2, crt, lactate, blood gas); urine output.

Eligibility criteria:
inclusion criteria: * operation time should be equal or greater than 2h, * patients older than 65 years old, * asa ⅱ or ⅲ. exclusion criteria: * clear arrhythmia, * need to apply peep, * peripheral vascular disease and arterial catheter contraindications.

Keywords: svv norepinephrine phenylephrine elderly
application of detecting circulating tumor cells in the accurate treatment of early stage lung adenocarcinoma

Conditions: Lung Adenocarcinoma, Stage I; Diagnoses Diseases; Circulating Tumor Cells; Treatment

Summary: in 2015-2016, 224,390 cases were newly diagnosed with lung cancer in usa. of all the cases, 83% are non-small cell lung cancer (nsclc). currently, the 5-year survival rate of nsclc patients is 21%, and more than 25% of early stage nsclc patients, who have undergone surgical treatment, will have a relapse or progression. circulating tumor cells (ctcs), which shed from the primary tumor into the vasculature or lymphatics, can be regarded as a new prognostic factors of metastatic process. thus far, ctcs-detection technologies can be divided into epithelial cell adhesion molecule (epcam)-based detection methods, e.g., the widely used cellsearch® and adnatest®,and epcam-independent detection methods, e.g., iset® and screencell®. herein, the investigators used a newly established approach, i.e., canpatroltm to detect ctcs in early stage lung adenocarcinoma cases. the investigator aim to explore whether ctcs detection prior to surgery can be contributive to the early diagnosis, or may help to predict the prognosis and guide the treatment strategy of early stage lung adenocarcinoma.


Eligibility criteria:
inclusion criteria: * stage i lung adenocarcinoma exclusion criteria: * cases with any new adjuvant treatment prior to surgery

Keywords: circulating tumor cells lung adenocarcinoma treatment early diagnosis
antioxidants in gestational diabetes

Conditions: Gestational Diabetes Mellitus

Summary: fasting and two hours postprandial blood sugar were done to all cases between 28 and 32 weeks and high blood sugar levels were found so cases were controlled by both diet and insulin. the 200 pregnant women with gestational diabetes mellitus were randomized using automated web based randomization system into 2 groups, group1 received 1 gram l-ascorbic acid (vitamin c )per day from the time of diagnosis until the time of delivery in addition to routine treatment of diabetes (diet \& insulin). group2 received only the treatment of diabetes

the 200 pregnant women with gestational diabetes mellitus were randomized using automated web based randomization system into 2 groups, group1 received 1 gram l-ascorbic acid oral once daily (vitamin c )per day from the time of diagnosis until the time of delivery in addition to routine treatment of diabetes (diet \& insulin). group2 received only the treatment of diabetes (diet and insulin

Eligibility criteria:
inclusion criteria: * women with the diagnosis of gdm exclusion criteria: * women with multiple pregnancies * chronic medical disorders e.g. anemia * hypertension * liver disease or renal disease * those with obstetric problems other than gdm (e.g. pre-eclampsia \& antepartum hemorrhage) or smokers and women with preexisting type i or ii diabetes mellitus were excluded from our study

Keywords: antioxidants gestational diabetes mellitus oxidative stress
intrauterine injection of human chorionic gonadotropin before embryo transfer in women with previous ivf failure

Conditions: Infertility; Invitro Fertilization

Summary: women with history of previous ivf cycle failure will be subjected to a fresh ivf cycle. at the time they will be undergoing embryo transfer, 50 iu of human chorionic gonadotropins diluted in 0.025ml of tissue culture media will be injected intrauterine by embryo transfer catheter 10 minutes before embryo transfer procedure.

infertile women with history of previous ivf cycle failure will be subjected top a fresh ivf cycle. following controlled ovarian hyperstimulation, ovum pick up and at the time they will be undergoing embryo transfer, 50 iu of human chorionic gonadotropins diluted in 0.025ml of tissue culture media will be injected intrauterine by embryo transfer catheter 10 minutes before embryo transfer procedure.

Eligibility criteria:
inclusion criteria: - women with previous ivf failure undergoing fresh ivf cycle exclusion criteria: * women with hydrosalpinges women with intrauterine lesion like submucous fibroid or polyps

Keywords: infertility invitro fertilization
tear film innovations ilux safety study

Conditions: Meibomian Gland Dysfunction; Evaporative Dry Eye

Summary: the objective of this study was to measure the temperature of the cornea and surrounding eye tissue temperature immediately after heating the eyelids with the ilux device using the protocol treatment profile. eligible participants attended one treatment visit, with follow-up one day following the procedure.

alcon research, llc, acquired tearfilm innovations, inc., in december 2018. this study was designed and conducted by tearfilm innovations, inc. the study results were collected, analyzed, and provided by tearfilm innovations, inc., to alcon research, llc.

Eligibility criteria:
key inclusion criteria: - sign written informed consent prior to study participation key exclusion criteria: * history of ocular surgery within 1 year * active ocular infection * ocular surface abnormality; lid surface abnormalities * pregnant, nursing or not utilizing adequate birth control measures * other protocol-specified exclusion criteria may apply